Frequently Asked Questions
Factors such as increased cases of STI and rising incidence of cervical cancer are acting as the major drivers for the global human papillomavirus infection drugs market.
Cipla Inc. (India), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Bristol-Myers Squibb Company (U.S.), GSK plc (U.K.), Nielsen Biosciences (U.S.), AIM ImmunoTech Inc (U.S.), Aclaris Therapeutics, Inc (U.S.).
Asia-Pacific dominates the market due to the surge in population and increase in government initiatives.
The major players are Cipla Inc. (India), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Bristol-Myers Squibb Company (U.S.), GSK plc (U.K.), Nielsen Biosciences (U.S.), AIM ImmunoTech Inc (U.S.), Aclaris Therapeutics, Inc (U.S.)
